Development
Takeda Pharmaceutical Company Limited
TAK
$15.30
-$0.225-1.45%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 2.05B | 2.13B | 2.19B | 4.01B | 5.20B |
| Total Receivables | 5.27B | 5.28B | 5.71B | 5.13B | 5.91B |
| Inventory | 8.30B | 7.74B | 7.49B | 7.42B | 7.03B |
| Prepaid Expenses | -- | -- | -- | -- | -- |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 1.62B | 1.34B | 1.71B | 1.48B | 1.54B |
| Total Current Assets | 17.23B | 16.48B | 17.10B | 18.04B | 19.69B |
|
|
|||||
| Total Current Assets | 17.23B | 16.48B | 17.10B | 18.04B | 19.69B |
| Net Property, Plant & Equipment | 13.06B | 12.68B | 12.42B | 12.72B | 12.56B |
| Long-term Investments | 36.26B | 35.49B | 35.84B | 36.04B | 35.57B |
| Goodwill | 36.26B | 35.49B | 35.84B | 36.04B | 35.57B |
| Total Other Intangibles | 29.06B | 29.47B | 31.22B | 32.12B | 28.56B |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 4.55B | 4.75B | 5.04B | 5.33B | 5.32B |
| Total Assets | 100.90B | 99.57B | 102.31B | 105.00B | 102.41B |
|
|
|||||
| Total Accounts Payable | 3.43B | 2.82B | 3.05B | 2.31B | 2.89B |
| Total Accrued Expenses | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | 1.93M | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 2.63B | 1.84B | 2.88B | 3.00B | 2.82B |
| Total Finance Division Other Current Liabilities | 10.13B | 11.19B | 11.37B | 13.35B | 11.25B |
| Total Other Current Liabilities | 10.13B | 11.19B | 11.37B | 13.35B | 11.25B |
| Total Current Liabilities | 16.19B | 15.85B | 17.30B | 18.67B | 16.96B |
|
|
|||||
| Total Current Liabilities | 16.19B | 15.85B | 17.30B | 18.67B | 16.96B |
| Long-Term Debt | 30.46B | 29.49B | 29.95B | 30.41B | 29.69B |
| Short-term Debt | -- | -- | -- | 1.93M | -- |
| Capital Leases | 3.85B | 3.85B | 3.43B | 3.16B | 3.82B |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 2.57B | 3.04B | 3.76B | 4.95B | 5.10B |
| Total Liabilities | 53.07B | 52.23B | 54.44B | 57.19B | 55.57B |
|
|
|||||
| Common Stock & APIC | 24.17B | 22.68B | 23.64B | 25.62B | 25.69B |
| Retained Earnings | 9.91B | 9.68B | 10.31B | 11.59B | 11.43B |
| Treasury Stock & Other | 13.75B | 14.98B | 13.92B | 10.59B | 9.71B |
| Total Common Equity | 47.83B | 47.34B | 47.87B | 47.80B | 46.83B |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 47.83B | 47.34B | 47.87B | 47.80B | 46.83B |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | 4.77M | 4.51M | 4.27M | 4.13M | 3.94M |
| Total Equity | 47.83B | 47.34B | 47.87B | 47.80B | 46.84B |
|
|
|||||